Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concent...
Petlife Pharmaceuticals reported revenue of $0 for fiscal year 2017, and net income of -$23.26 million. In Q2 2018 (the quarter ended February 28, 2018) revenue was $0.
Figures from company filings; latest fiscal year ended August 31, 2017.
No profile data available.